The pharmaceutical standard of care for lung cancer is primarily intravenous chemotherapy drugs, which have limited efficacy because of low drug concentration delivered to the lungs due to blood volume dilution.
Quench Medical’s inhalation technology delivers the drug directly to tumor tissues in the lung thereby enhancing its efficacy due to increased local drug concentration in the lung, and decreased systemic toxicity due to decreased systemic drug levels in the circulation.
Our new method delivers the chemotherapeutic drug via dry powder inhalation to reach lung tumors directly, in lower doses, in order to maximize the effectiveness and safety of the cancer treatment.
Directly targeting lung tumors with inhaled chemotherapy to increase efficacy while minimizing systemic toxicity
Highly efficient delivery of corticosteroid medications to the undertreated small airways to reduce inflammation
Deep penetration of antibiotic therapies to treat infections with high efficiency